Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986205 plus nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma
2017-002499-14Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing BMS-986205 + nivolumab with nivolumab (2 arms). Primary endpoint: Safety-only assessments after protocol revision. Started Oct 2017; status: completed.
02
Drugs
linrodostatnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-002499-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002499-14.